TABLE 1.
Common name | Chemical structure | Steroid class | EC50 (±SD) | IC50 (±SD) | Maximum serum level | Physiological presence | Common use | References |
---|---|---|---|---|---|---|---|---|
Progesterone | Progestagen | 0.003 (±0.001) | 0.006 (±0.002) | 3 nM (male) | Yes | Birth control | Löfgren and Bäckström (1990) | |
60 nM (female) | ||||||||
Stanozolol | Androgen | 0.285 (±0.328) | 0.194 (±0.045) | ND | No | Anabolic-Androgenic Steroids (AAS) | ND | |
Pregnenolone | Progestagen | 0.073 (±0.016) | 0.199 (±0.008) | 12 nM | Yes | Endometriosis | Hill et al. (1999) | |
Dydrogesterone | Progestagen | 0.130 (±0.103) | 0.245 (±0.042) | 52 nM | No | Luteal insufficiency infertility | Abdel-Hamid et al. (2006) | |
Estropipate | Estrogen | 0.161 (±0.017) | 0.288 (±0.010) | 0.29 nM | No | Ovarian failure | Barnes and Levrant (2007) | |
Medrysone | Corticosteroid | 0.240 (±0.103) | 0.569 (±0.275) | ND | No | Anti-inflammatory | ND | |
Deoxycorticosterone | Mineralocorticoid | 0.302 (±0.062) | 0.523 (±0.081) | 0.19 nM | Yes | Adrenocortical insufficiency | Oddie et al. (1972) | |
Epiandrosterone | Androgen | 0.209 (±0.033) | 0.628 (±0.102) | 9 nM | Yes | AAS | Lewis et al. (1997) | |
Nandrolone | Androgen | 0.306 (±0.033) | 0.711 (±0.109) | 19 nM | No | AAS; Anemia | Bagchus et al. (2005) | |
Testosterone | Androgen | 0.407 (±0.062) | 1,107 (±0.157) | 11.6 nM | Yes | Sexual dysfunction (men); hot flashes (women) | Groepenhoff et al. (2021) | |
Dehydroisoandosterone 3-acetate (DHEA) | Androgen | 0.593 (±0.043) | 1,745 (±0.488) | 53 nM | Yes | Depression, Supplement | Habib et al. (2021) |